We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Deciphera Pharmaceuticals Inc | NASDAQ:DCPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 0.08% | 25.51 | 25.51 | 25.52 | 25.53 | 25.51 | 25.53 | 346,165 | 15:37:52 |
– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –
– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –
– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-line GIST Patients with Mutations in KIT Exon 11 and 17/18 Initiated with First Sites Open for Enrollment –
– DCC-3116 Combination Escalation Cohorts with QINLOCK and with Encorafenib and Cetuximab Initiated with First Site Open for Enrollment; Combination Dose Escalation Cohorts with MEK and KRAS G12C Inhibitors Ongoing –
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
“QINLOCK delivered record performance in the second quarter based on continued growth in the U.S. and around the world. Moving into a significant second half of 2023, we are looking forward to the top-line results from the MOTION study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT), which has the potential to become our second approved medicine,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “Additionally, we have opened the first sites for INSIGHT, the pivotal Phase 3 study of QINLOCK versus sunitinib in second-line gastrointestinal stromal tumor (GIST) patients with mutations in KIT exon 11 and 17 or 18 and for additional combination cohorts of our ULK inhibitor DCC-3116, one in combination with QINLOCK and another in combination with encorafenib and cetuximab. We are on track to submit an Investigational New Drug application to the FDA for DCC-3084, a potential best-in-class pan-RAF inhibitor, in the fourth quarter.”
Mr. Hoerter continued, “We are proud of the significant progress across both our early-stage and late-stage programs that we have already achieved in the first half of 2023. In addition to the INTRIGUE Phase 3 ctDNA analysis presented at the ASCO Plenary Session in the first quarter, we also presented eight poster presentations at AACR that showcased the depth and breadth of our kinase switch-control research engine along with the nomination of our newest development candidate, DCC-3009, a potential best-in-class pan-KIT inhibitor. At ASCO in June, we had one encore presentation of our INTRIGUE Phase 3 ctDNA analysis and three poster presentations, including overall survival and long-term safety data from the INTRIGUE Phase 3 study of QINLOCK. Finally, on behalf of everyone at Deciphera, I would like to thank Dan Flynn for his dedication to Deciphera’s founding vision of improving the lives of people with cancer, and for trailblazing the innovations that have made all these advancements possible. We are excited to build upon this foundation with Dash Dhanak as our new Chief Scientific Officer.”
Second Quarter 2023 Highlights and Upcoming Milestones
QINLOCK® (ripretinib)
Vimseltinib
DCC-3116
DCC-3084
DCC-3009
Kinase Switch-Control Research Engine
Corporate Update
Second Quarter 2023 Financial Results
Conference Call and Webcast
Deciphera will host a conference call and webcast to discuss this announcement today, August 9, 2023, at 8:00 AM ET. The conference call may be accessed via this link: https://register.vevent.com/register/BI74ff2d04fe8541f48da1cf0ad35339ae. A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors & News” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations and timing regarding the potential for our preclinical and/or clinical stage pipeline assets to be first-in-class and/or best-in-class treatments; our Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18; plans to announce top-line results from the pivotal Phase 3 MOTION study of vimseltinib in TGCT patients in the fourth quarter of 2023 and the potential for vimseltinib to become our second approved medicine; plans to present updated data from the phase 1/2 study of vimseltinib in TGCT patients in the fourth quarter of 2023; plans for our ongoing phase 1/2 studies of DCC-3116; and cash guidance. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, our ability to successfully demonstrate the efficacy and safety of our drug or drug candidates, the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
The Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks and Deciphera is a trademark of Deciphera Pharmaceuticals, LLC.
Deciphera Pharmaceuticals, Inc. Consolidated Balance Sheets (Unaudited, in thousands, except share and per share amounts)
June 30, 2023
December 31, 2022
Assets
Current assets:
Cash and cash equivalents
$
81,394
$
64,741
Short-term marketable securities
247,346
259,745
Accounts receivable, net
23,200
22,429
Inventory
25,343
20,561
Prepaid expenses and other current assets
27,767
25,482
Total current assets
405,050
392,958
Long-term marketable securities
60,683
14,550
Long-term investments—restricted and other long-term assets
3,339
3,277
Property and equipment, net
6,213
6,707
Operating lease assets
34,333
36,547
Total assets
$
509,618
$
454,039
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$
18,211
$
18,612
Accrued expenses and other current liabilities
59,455
64,622
Operating lease liabilities
3,368
3,235
Total current liabilities
81,034
86,469
Operating lease liabilities, net of current portion
24,154
25,879
Total liabilities
105,188
112,348
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized; no shares issued or outstanding
—
—
Common stock, $0.01 par value per share; 125,000,000 shares authorized; 78,772,870 shares and 67,637,351 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively
788
676
Additional paid-in capital
1,736,143
1,575,361
Accumulated other comprehensive income (loss)
(967
)
(983
)
Accumulated deficit
(1,331,534
)
(1,233,363
)
Total stockholders' equity
404,430
341,691
Total liabilities and stockholders' equity
$
509,618
$
454,039
Deciphera Pharmaceuticals, Inc. Consolidated Statements of Operations (Unaudited, in thousands, except share and per share amounts)
Three Months Ended June 30,
Six Months Ended June 30,
2023
2022
2023
2022
Revenues:
Product revenues, net
$
37,320
$
31,497
$
70,542
$
60,306
Collaboration revenues
984
997
1,207
1,411
Total revenues
38,304
32,494
71,749
61,717
Cost and operating expenses:
Cost of sales
173
1,799
661
2,181
Research and development
58,296
44,858
113,061
92,270
Selling, general, and administrative
32,610
29,625
64,059
57,946
Total cost and operating expenses
91,079
76,282
177,781
152,397
Loss from operations
(52,775
)
(43,788
)
(106,032
)
(90,680
)
Other income (expense):
Interest and other income, net
4,213
727
7,861
727
Total other income (expense), net
4,213
727
7,861
727
Net loss
$
(48,562
)
$
(43,061
)
$
(98,171
)
$
(89,953
)
Net loss per share—basic and diluted
$
(0.57
)
$
(0.60
)
$
(1.17
)
$
(1.31
)
Weighted average common shares outstanding—basic and diluted
85,020,344
72,133,428
83,854,959
68,441,998
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809788143/en/
Investor Relations: Maghan Meyers Argot Partners Deciphera@argotpartners.com 212-600-1902 Media: David Rosen Argot Partners david.rosen@argotpartners.com 212-600-1902
1 Year Deciphera Pharmaceuticals Chart |
1 Month Deciphera Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions